All In Biotech

Drug Trial Radar · NCT05248802

DLBS2411 Treatment For Functional Dyspepsia

Randomized Controlled Trial of DLBS2411 Treatment For Functional Dyspepsia

Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Dec 9, 2022

Primary completion

Oct 1, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients with functional dyspepsia (FD), and an additional 8 weeks after end of therapy (Week 12) for follow-up visit. The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. The mechanism altogether demonstrated DLBS2411's protective capacity to the gastric and colon mucosa by promoting mucous synthesis and stimulating mucosal blood flow. Having such mechanisms of action, DLBS2411 is hypothesized to benefit subjects with gastric acid disorders such as in functional dyspepsia, gastro-intestinal reflux disease (GERD), peptic-ulcer, and irritable bowel syndrome (IBS).

Conditions

  • Functional Dyspepsia

Interventions

  • Placebo caplet of DLBS2411Drug

    1 caplet of placebo DLBS2411, twice daily

  • DLBS2411Drug

    1 caplet of DLBS2411 250 mg, twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short-Form Nepean Dyspepsia Index (SF-NDI)Time frame: Week 4

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Internal Medicine, Dr. Kariadi General Hospital

    Semarang, Central Java, Indonesia

  • Department of Internal Medicine, Universitas Sebelas Maret (UNS) Hospital

    Sukoharjo, Central Java, Indonesia

  • Department of Internal Medicine, Dr. Moewardi Hospital

    Surakarta, Central Java, Indonesia

  • Department of Internal Medicine, Budhi Asih Hospital

    Jakarta, DKI Jakarta, Indonesia

  • Department of Internal Medicine, Fatmawati General Hospital

    Jakarta, DKI Jakarta, Indonesia

  • Department of Internal Medicine, Pasar Rebo Hospital

    Jakarta, DKI Jakarta, Indonesia

  • Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia

    Surabaya, East Java, Indonesia

  • Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital

    Jakarta, Jakarta Special Capital Region, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.